Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children

BACKGROUND: The antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV. Nevirapine is a known inhibitor of cytochrome P450 3A4, which metabolizes artemether and lumefantrine...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Liusheng, Carey, Vincent, Lindsey, Jane C., Marzan, Florence, Gingrich, David, Graham, Bobbie, Barlow-Mosha, Linda, Ssemambo, Phionah K., Kamthunzi, Portia, Nachman, Sharon, Parikh, Sunil, Aweeka, Francesca T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655345/
https://www.ncbi.nlm.nih.gov/pubmed/29065172
http://dx.doi.org/10.1371/journal.pone.0186589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655345/
https://www.ncbi.nlm.nih.gov/pubmed/29065172
http://dx.doi.org/10.1371/journal.pone.0186589

Ejemplares similares